MARKET

VNDA

VNDA

Vanda Pharms
NASDAQ

Real-time Quotes | Nasdaq Last Sale

11.05
-0.07
-0.63%
After Hours: 11.05 0 0.00% 17:48 05/28 EDT
OPEN
11.21
PREV CLOSE
11.12
HIGH
11.22
LOW
10.67
VOLUME
944.05K
TURNOVER
--
52 WEEK HIGH
17.85
52 WEEK LOW
7.12
MARKET CAP
602.78M
P/E (TTM)
5.17
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 5 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average VNDA stock price target is 15.00 with a high estimate of 25.00 and a low estimate of 7.00.

EPS

VNDA News

More
Healthcare And Biotechnology Dashboard - Update
Seeking Alpha - Article · 2d ago
Vanda Pharmaceuticals Announces Virtual 2020 Stockholder Meeting
Vanda Pharmaceuticals Inc. ("Vanda") (Nasdaq: VNDA), announced today that Vanda will hold its 2020 Annual Meeting of Stockholders (the "2020 Annual Meeting") in a virtual-only format due to public health concerns related to the COVID-19 pandemic and to protect
PR Newswire · 2d ago
Vanda Pharma Reports Federal District Court Granted Co. Motion To Dismiss False Claims Act Suit Filed Against Co.
Benzinga · 05/20 21:20
Vanda Pharmaceuticals Wins Motion To Dismiss False Claims Act Lawsuit
Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the Federal District Court in Washington D.C. granted Vanda's motion to dismiss a False Claims Act lawsuit filed against the company.
PR Newswire · 05/20 21:20
1 Pharma Stock to Avoid at All Costs
No matter how much courage an investor has, investing in cheap stocks that have pending whistleblower lawsuits against them just isn't a good idea.
Motley Fool · 05/15 15:43
Vanda on go to refile Hetlioz application in U.S.
Seeking Alpha - Article · 05/13 12:51
Vanda Pharmaceuticals Announces Agreement With FDA On Resubmission Of Application For HETLIOZ For The Treatment Of Patients With Smith-Magenis Syndrome
Benzinga · 05/13 11:02
Vanda Pharmaceuticals Announces Agreement with FDA on Resubmission of the Application for HETLIOZ® for the Treatment of Patients with Smith-Magenis Syndrome
Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that following the completion of a Type A Meeting with the U.S. Food and Drug Administration (FDA) on May 8, 2020, it has reached agreement with the FDA to resubmit its application for HETLIOZ®
PR Newswire · 05/13 11:00

Industry

Biotechnology & Medical Research
+0.35%
Pharmaceuticals & Medical Research
+1.04%

Hot Stocks

Symbol
Price
%Change

About VNDA

Vanda Pharmaceuticals Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of therapies to address unmet medical needs. Its product portfolio includes HETLIOZ (tasimelteon), Fanapt (iloperidone), Tradipitant (VLY-686), Trichostatin A and AQW051. It offers HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24). HETLIOZ is in clinical development for the treatment of Pediatric Non-24, Jet Lag Disorder and Smith-Magenis Syndrome. It offers Fanapt for the treatment of schizophrenia. Fanapt has potential utility in various other disorders. Tradipitant is a small molecule neurokinin-1 receptor (NK-1R) antagonist, which is in clinical development for the treatment of chronic pruritus in atopic dermatitis. Trichostatin A is a small molecule histone deacetylase (HDAC) inhibitor. AQW051 is a Phase II alpha-7 nicotinic acetylcholine receptor partial agonist. AQW051 is indicated for the treatment of central nervous system disorders.
More

Webull offers kinds of Vanda Pharmaceuticals Inc. stock information, including NASDAQ:VNDA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, VNDA stock news, and many more online research tools to help you make informed decisions.